Center for Thoracic Oncology

Our Team

Contact

Boston Medical Center
Moakley Building
830 Harrison Avenue, Suite 3400
Boston, MA 02118

Hours: 8:00AM - 5:00PM
Phone: 617.638.5600
Fax: 617.638.7382
 

Ken S. Zaner, MD, PhD

Clinical Director, Center for Cancer and Blood Disorders
Attending Physician, Center for Thoracic Oncology
Attending Physician, Department of Medicine Hematology/Oncology
Associate Professor of Medicine, Boston University School of Medicine

Special Interests
Lung cancer; urologic malignancies; gastrointestinal malignancies

Education and Training
Publications

Education and Training

College
Brooklyn College, Brooklyn, New York

Medical School
State University of New York - Downstate Medical Center

Residency
Resident in Medicine, State University of New York, Downstate Medical Center

Fellowship
Clinical and Research Fellow, Hematology-Oncology Unit, Massachusetts General Hospital, Boston, MA

Board Certifications
American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology

Publications

Eggleton, P., B. Ghebrihiwet, K. Sastry, J. Coburn, K.S. Zaner, K.B.M. Reid and A.I. Tauber. Identification of a gC1q Binding Protein (gC1q-R) on the Surface of Human Neutrophils: Subcellular Localization and Binding Properties in Comparison with cC1q-R. J. Clinical Investigation. 1995; 95:1569-1578.

Hartshorn, K.L., M. White, D. Voelker, J. Coburn, K. Zaner and E. Crouch. Mechanism of Binding of Surfactant Protein D. to Influenza A Viruses: importance of binding to haemagglutinin to Antiviral Activity. Biochem. J. 2000; 351 Pt 2:449-58, 2000 Oct 15.

Akerley, W., R. Lee, K. Zaner, N. Ready, T. Mega, H. Safran and T. Kennedy. Phase II Trial of Weekly Paclitaxel and Gemcitabine for Previously Untreated Stage IIIB-IV Non-Small-Cell Lung Cancer. Cancer 2006;107:1050-4.

Dragovich, T., S. McCoy, S. Urba, K. Zaner, A. Baker, Jiang Wang, Karen Winstead, Chris Hackett, John Bishop, C. Fenoglio-Preiser, C. Fenoglio-Preiser, C. Blanke, J. Abbruzzese. SWOG 0127: Phase II Trial of Erlotinib in Gastroesophageal Junction GEJ and Gastric Adenocarcinomas. Journal of Clinical Oncology 2006;24:4922-4927.